Allergy Therapeutics plc, a biotechnology company specializing in allergy vaccines, has announced that its Chief Executive Officer, Manuel Llobet, has exercised options over 1,676,200 ordinary shares in the company. These shares were granted at nominal value under the company's 2013 Long Term Incentive Plan and were subsequently admitted to trading on December 1, 2023. Following the exercise of these options, Llobet now holds a total of 5,001,200 ordinary shares in the company, representing approximately 0.10% of the issued share capital.

In addition to Llobet's exercise of options, the company also issued 888,967 ordinary shares in satisfaction of the exercise of share options by certain other current and former employees. These shares were also admitted to trading on December 1, 2023. The share options were exercised prior to or on November 16, 2023, as a result of recent equity financing that constituted a change of control for the purposes of the company's Long Term Share Incentive Plan.

The new ordinary shares rank pari passu with the company's existing shares. As of December 13, 2023, Allergy Therapeutics has 4,766,439,938 ordinary shares in issue, with no shares held in treasury. The total number of voting rights in the company is therefore 4,766,439,938. Shareholders may use this figure as the denominator for calculating their interest in the share capital of the company.

Allergy Therapeutics is an international commercial biotechnology company focused on the treatment and diagnosis of allergic disorders. The company sells proprietary and third-party products in major European countries and through distribution agreements in additional countries. Its pipeline of products in clinical development includes vaccines for grass, tree, house dust mite, and peanut allergies.